SLC35C2 Inhibitors

SLC35C2 inhibitors encompass a range of chemical compounds targeting various aspects of cellular metabolism and signaling pathways, particularly focusing on hypoxia response, GDP-fucose transport, and Notch signaling pathways. These inhibitors provide essential tools for understanding the role of SLC35C2 in these processes. Inhibitors like 2-Deoxy-D-glucose and Cobalt(II) chloride, which affect glycolysis and mimic hypoxic conditions respectively, can shed light on how SLC35C2 functions under hypoxic stress and its role in cellular responses to such conditions. Compounds such as Brefeldin A, Tunicamycin, and Swainsonine, which disrupt different aspects of glycosylation and Golgi function, are critical for exploring the role of SLC35C2 in GDP-fucose transport and fucosylation processes.

Inhibitors of the Notch signaling pathway, like DAPT and Dibenzazepine (Deshydroxy LY 411575), offer insights into how SLC35C2 may influence this pathway through its role in fucosylation. These compounds can help elucidate the interplay between SLC35C2 function and Notch signaling regulation. Additionally, compounds targeting related pathways, such as Bay 11-7082 (NF-κB inhibitor), PD173074 (FGFR inhibitor), and WZ4003 (NUAK1 inhibitor), provide a broader understanding of the cellular networks and responses where SLC35C2 may play a role. In summary, the use of these inhibitors is crucial for dissecting the role of SLC35C2 in hypoxia response, GDP-fucose transport, and Notch signaling pathways. By studying the effects of these compounds on SLC35C2-associated processes, researchers can gain valuable insights into the molecular mechanisms governing these important cellular functions and the role of SLC35C2 in maintaining cellular homeostasis.